Amarin's New Vascepa Data Shows Significant Reduction In Heart Attack Subtypes

New data shows that Amarin Corporation plc's AMRN Vascepa/Vazkepa (icosapent ethyl) significantly reduced ST-segment and non-ST elevation myocardial infarction (NSTEMI) and other MI subtypes in patients with cardiovascular disease or diabetes with risk factors.
The REDUCE-IT study data presented show STEMI was significantly reduced by 40% following treatment with icosapent ethyl (IPE) compared to placebo.
IPE also significantly reduced NSTEMI by 27%.
Related: Amarin Still Suspends FY22 Guidance On Generic Challenges.
"This analysis of REDUCE-IT clearly shows that IPE 4 g/day as an adjunct to statin therapy in high-risk patients with residual hypertriglyceridemia provides a large and significant reduction in heart attacks," said Deepak Bhatt, principal investigator of the REDUCE-IT trial.
In time to first event analyses, MI was significantly reduced with IPE treatment, with a number needed to treat (NNT) of 39.
There were clinically meaningful and statistically significant reductions in MI subtypes, including MI leading to cardiac arrest and resuscitated MI.
IPE also significantly reduced the overall burden of total (first and subsequent) STEMI and total NSTEMI versus placebo.
Price Action: AMRN shares are down 0.38% at $1.29 on the last check Friday.